ClinicalTrials.gg
RecruitingNCT02840747Updated Nov 4, 2026

Tissue Repository: CTCL Collection Protocol

An observational study in Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis and Sézary Syndrome, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Columbia University · Observational

How we know

Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States — 33 open to participants now, 45 under way, none of them phase 3. Lymphoma, T-Cell, Cutaneous · United States.

Planned enrollment
9th of 41
400 · median 60
Started
2016
with 8 others
Observational
41 of 434
10 open now
Primary completion
2027-08
later than 19 of 43 live
Registered
366th of 434
by date

Among the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, this one is the 9th largest by planned enrollment of the 41 observational ones that give a count, is one of 9 that started in 2016, is one of 41 observational ones, reaches primary completion later than 19 of the 43 other live ones, and was the 366th registered.

Lymphoma, T-Cell, Cutaneous

554 studies on the registry are indexed under Lymphoma, T-Cell, Cutaneous; 63 are open to participants now.

Browse Lymphoma, T-Cell, Cutaneous studies →

Open to participants now

33 of the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Lymphoma, T-Cell, Cutaneous studies recruiting now, 33 (75%) set no upper age limit and 6 (14%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, or all of them as a file.
02

Study summary

This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL). The purpose of this study is to establish a protocol for the collection and storage of tissue samples from patients with CTCL for future research studies. Collection and storage of tissue samples from control patients will also be carried out.

Read the detailed description

CTCL is a heterogeneous group of non-Hodgkin's lymphomas characterized by chronic inflammation and accumulation of malignant T cells in the skin. In order to carry out research to expand the knowledge and develop more effective treatments, tissue samples from CTCL patients with presumed or known disorders are required and tissue samples from control patients will be required to compare the differences between affected and healthy populations.

Scientists will be able to test new ideas and new technologies that are not apparent or available at the present moment from this tissue repository in the future. This type of information will thus be of great advantage to future patients with these diseases.

03

Conditions studied

  • Lymphoma, T-Cell, Cutaneous
  • Lymphomatoid Papulosis
  • Sézary Syndrome

Keywords

  • Lymphomatoid Papulosis
  • Sézary Syndrome
  • T-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This protocol is for the collection of biological specimens from patients who fall into the following three groups:

  1. Patients with diagnosis of cutaneous T cell lymphoma (diagnosed according to the WHO-EORTC criteria)
  2. Patients with benign dermatoses, including but not limited to psoriasis, eczema, and dermatitis.
  3. Healthy controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with CTCL or Lymphomatoid Papulosis (LYP): a clinical or histologic diagnosis of a) newly diagnosed, b) progressive, or c) CTCL or LYP who are initiating or changing therapy.
  • Patients with Sézary Syndrome (SS) or stage IV B CTCL as defined by blood involvement on flow cytometry or morphology: (1) ≥1000/μL Sézary cells by morphology; (2) Cluster of differentiation 4 (CD4)/cluster of differentiation 8 (CD8) ratio ≥10; (3) CD4+cluster of differentiation 7 (CD7)- cells ≥40 percent; (4) or CD4+cluster of differentiation 26 (CD26)- cells ≥30 percent.
  • Ability to understand and willing to sign a willing document.
  • Age ≥ 18 years.

Inclusion Criteria for Age and Sex Matched Controls:

  • Matched for sex, and age +/- 10 years.
  • Ability to sign informed consent document.
  • Patients with or without benign inflammatory skin conditions including, but not limited to, eczema, psoriasis, or dermatitis or Patients without skin conditions requiring treatment with systemic , biologic, or chemotherapeutic agents.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of previous lymphoma other than CTCL or SS or LYP.
  • Medical illnesses with potential suppressive or activating impact on immune and bowel function as judged by the investigator.
  • Current, viable pregnancy.
  • Anemia with a documented laboratory value of \<7.5 g/dl within the past 6 months.

Exclusion Criteria for Age and Sex Matched Controls:

  • Previous history of CTCL, SS, LYP, or any lymphoma.
  • Previous history of (HIV) infection.
  • Anemia with a documented hemoglobin laboratory value of \<7.5 g/dl within the past 6 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with CTCL

    Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria).

  • Patients with benign dermatoses

    Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis.

  • Healthy Controls

    Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers.

06

What researchers measure

Primary outcomes

  1. Number of biological specimen collections

    This is a collection protocol to establish a tissue repository for samples from patients with CTCL.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Jul 2016, a primary completion of Aug 2027 and a completion of Aug 2027. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Aug 2027 and completion Oct 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2016
First posted
Jul 21, 2016
Start
Jul 2016
Primary completionEst.
Aug 2027was Oct 2026
CompletionEst.
Aug 2027was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Aug 2027
Nov 4, 2026
Study completion
Oct 2026→Aug 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Oct 2026→Aug 2027
    Study completion Oct 2026→Aug 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02840747
Responsible party
Sponsor
First posted
Jul 21, 2016
Start date
Jul 2016
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Larisa J. Geskin, MD
Contact
ljg2145@cumc.columbia.edu
Brigit Lapolla
Contact
bl2963@cumc.columbia.edu
Larisa J. Geskin, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion